March 21, 2026 a 09:00 pm

BIIB: Analysts Ratings - Biogen Inc.

Historical Stock Grades

The most recent data reveals a focused sentiment trend for Biogen Inc. Among analysts, 'Buy' and 'Hold' recommendations dominate. Notably, there is a concentration of opinions towards the middle of the spectrum, reflecting a hesitance to commit to aggressive positions given the currently ambiguous market environment.

Rating	Number	Score
Strong Buy	1
Buy	14
Hold	20
Sell	1
Strong Sell	0

Sentiment Development

The sentiment trend reveals a noticeable increase in cautious 'Hold' ratings over the months, shifting from the previously more optimistic stance with 'Strong Buy' recommendations. Analysts seem to be digesting mixed signals from the market as they assess Biogen's strategies and pipeline developments.

• The total number of ratings has remained relatively stable, yet the quality has shifted towards a more neutral standpoint.
• 'Strong Buy' recommendations have decreased over time, aligning with the company's recent performance and market dynamics.

Percentage Trends

A marked shift is noted in the percentage of recommendations, showcasing a movement towards more defensive positions. Recent months have seen a decline in 'Strong Buy' with a corresponding rise in 'Hold' recommendations. This suggests a market sentiment leaning towards stability rather than aggressive growth expectations.

• Strong Buy recommendations have fallen from a high of 7% to 1%, indicating cautious outlooks.
• Hold recommendations have seen a gradual increase, peaking at 46% recently.
• Buy recommendations have remained a constant yet fluctuating category within the analyst community.

Latest Analyst Recommendations

Recent analyst reviews indicate a sustained sentiment with prevailing 'Maintain' recommendations. Most analysts have retained their outlook, suggesting a period of observation and minimal changes in expectations for Biogen's performance.

Date	New Recommendation	Last Recommendation	Publisher
2026-03-17	Reduce	Reduce	HSBC
2026-02-10	Neutral	Neutral	Wedbush
2026-02-09	Neutral	Neutral	Piper Sandler
2026-02-09	Market Perform	Market Perform	BMO Capital
2026-02-09	Equal Weight	Equal Weight	Wells Fargo

Analyst Recommendations with Change of Opinion

In recent months, some analysts have adjusted their recommendations, indicating shifts in market perception. Notably, there have been downgrades in ratings, pointing to a more conservative stance taken by analysts amid market volatility.

Date	New Recommendation	Last Recommendation	Publisher
2025-12-10	Reduce	Hold	HSBC
2025-11-06	Buy	Hold	Stifel
2025-04-04	Hold	Buy	Argus Research
2025-01-02	Neutral	Overweight	Piper Sandler
2024-12-20	Market Perform	Outperform	BMO Capital

Interpretation

The current analyst sentiment towards Biogen Inc. suggests caution amidst recent market dynamics and business developments. While the majority of analysts maintain a 'Hold' or 'Neutral' stance, recent downgrades indicate potential apprehension about the company's near-term prospects. There is evidence of growing uncertainty as analysts adjust their expectations in light of Biogen's performance and the evolving market environment. Overall, stability in recommendations also suggests limited volatility in Biogen's projected performance as perceived by many analysts.

Conclusion

In summary, the analysis of Biogen Inc.'s stock ratings reveals a cautious but stable sentiment amongst analysts. While the company remains a key player in the biotechnology sector, recent downgrades and a swing towards 'Hold' ratings suggest a more guarded approach by the analyst community. Opportunities for growth exist, particularly in the development and delivery of new therapies, but these are tempered by competitive pressures and market uncertainties. Monitoring Biogen's performance closely in the coming months will be essential for stakeholders and analysts alike to assess potential shifts in the company's outlook.